VLP-Polio

CanSino Biologics Inc. · Phase 1 active Biologic

At a glance

Generic name	VLP-Polio
Sponsor	CanSino Biologics Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers (PHASE1, PHASE2)
A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults (PHASE1)
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VLP-Polio CI brief — competitive landscape report
VLP-Polio updates RSS · CI watch RSS
CanSino Biologics Inc. portfolio CI